1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

ESLAW
Estrella Immunopharma, Inc.US flagNASDAQ Capital Market
0.06
USD
-0.02
- -
19.34MMarket Cap

Total Valuation

Estrella Immunopharma, Inc. carries a market capitalization of 19.34M, placing it among publicly traded companies globally. Its enterprise value stands at 5.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap19.34M
Enterprise Value5.45M

Share Statistics

Estrella Immunopharma, Inc. currently has 43.03M shares outstanding.

Shares Outstanding43.03M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio-0.75
P/TBV Ratio-0.75
P/FCF RatioN/A
P/OCF RatioN/A

Financial Position

Estrella Immunopharma, Inc. maintains a current ratio of 0.20, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

Current Ratio0.20
Quick Ratio0.04
Debt / EquityN/A
Debt / EBITDAN/A
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-318.93
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-25.00
Effective Tax RateN/A

Stock Price Statistics

Estrella Immunopharma, Inc.'s stock has declined approximately -21.73138% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.10.

Beta (5Y)N/A
52-Week Price Change-21.73138%
50-Day Moving Average0.10
200-Day Moving Average0.10
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -9.79M, while operating income came in at -9.79M.

RevenueN/A
Gross ProfitN/A
Operating Income-9.79M
Pretax Income-10.01M
Net Income-10.01M
EBITDA-9.79M
EBIT-9.79M
Earnings Per Share (EPS)N/A

Balance Sheet

Total book value stands at -7.43M, with working capital of -7.43M providing operational flexibility.

Cash & Cash Equivalents146,670.00
Total DebtN/A
Net Debt-146,670.00
Equity (Book Value)-7.43M
Book Value Per Share-0.17
Working Capital-7.43M

Cash Flow

Estrella Immunopharma, Inc. produced -9.38M in operating cash flow over the past twelve months.

Operating Cash Flow-9.38M
Capital ExpendituresN/A
Free Cash Flow-9.38M
FCF Per ShareN/A

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-146.82
FCF YieldN/A

Scores

Estrella Immunopharma, Inc. posts an Altman Z-Score of -54.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-54.14